Last reviewed · How we verify
IOBENGUANE I 131
IOBENGUANE I 131 is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | IOBENGUANE I 131 |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2018 |
Approved indications
Common side effects
Key clinical trials
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (PHASE1)
- MIBG for Refractory Neuroblastoma and Pheochromocytoma (NA)
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (PHASE2)
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (PHASE2)
- 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |